Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 17, 2026.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. has 64.75M shares outstanding.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. maintains a current ratio of 2.86, meaning it holds 2.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -7,320.56, indicating conservative leverage, while an interest coverage ratio of -60.13 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -97.15, reflecting losses generated across the asset base. The company generates approximately 1.50M in revenue per employee across its workforce of 359.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.64 indicates how many times Mirum Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Mirum Pharmaceuticals, Inc. recorded 2.34M in income tax expense. The company reported a pretax loss of -750.60M and -752.94M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Mirum Pharmaceuticals, Inc. generated 540.99M in revenue and converted that into -752.94M in net income, yielding earnings per share of -13.03. EBITDA reached -707.26M, while operating income came in at -79.85M.

As of June 30, 2026, Mirum Pharmaceuticals, Inc. holds 383.64M in cash and equivalents against 667.81M in total debt, resulting in a net debt position of 367.06M. Total book value stands at -9.12M, with working capital of 361.96M providing operational flexibility.

Mirum Pharmaceuticals, Inc. produced -198.93M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -31.93M in capital expenditures, free cash flow totaled -230.85M - equivalent to -4.11 per share.

Over the twelve months ended June 30, 2026, Mirum Pharmaceuticals, Inc. posted a gross margin of 81.72, reflecting its pricing power and cost economics. The operating margin of -14.76 and net profit margin of -139.18 provide insight into operational efficiency.